GENOMIC VISION: Promising Results from the New Telomere Length Assay (TLA) in the Scope of Development of Cancer Therapies

BAGNEUX, France–(BUSINESS WIRE)–Regulatory News:

GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome, announced today promising results from its strategic research partnership with the Children’s Medical Research Institute (CMRI, Sydney) with the purpose of understanding the effects of telomere length on complex diseases, notably cardiovascular diseases and cancers.

Telomeres are regions in the genome which protect the ends of the chromosome from deterioration and fusion with neighboring chromosomes. Human telomeres are linked with both cancer and ageing and as such, there is a considerable interest in determining the length of these essential structures.

The partnership set up between Prof. Hilda Pickett’s laboratory and Genomic Vision’s team on May 2018 aimed to explore the correlation between telomere shortening and cancer onset. Genomic Vision’s novel approach based on molecular combing, called the “Telomere Length Assay (TLA)”, is suitable to distinguish variations in telomere length with high accuracy and great reproducibility in human and other mammalian models.

Molecular combing technology has already been used by Genomic Vision and other laboratories to measure Telomere length, but it is the first time TLA is developed in the perspective of a therapeutic application.

Aaron Bensimon, Co-Founder and CEO of Genomic Vision declared: “After one year of collaborative work with CMRI, we are happy to report our first promising result on Telomere Length Assay (TLA). Associate Professor Hilda Pickett’s research investigates telomere stability and telomere length maintenance mechanisms in cancer. Pickett’s laboratory has used the Genomic Vision molecular combing platform and the TLA to measure the length of individual telomere in cancer cells. This technology can be applied to mouse and human models to investigate diseases involving telomere stability. The TLA combines a simple wet-lab protocol with Genomic Vision’s FiberStudio® software. The results, obtained from our proprietary technology and the collaboration with CMRI, confirm that molecular combing provides strong advantages over classical methods in the field of telomere length measurement and studies of telomere modification.”

Associate Professor Hilda Pickett, Children Medical Research Institute (CMRI), added: “We greatly appreciate our partnership with Genomic Vision. The collaboration has existed for about one year during which we have been progressing quickly on TLA to detect and analyze telomeres in cells. Using TLA, it is possible to discriminate individual telomere lengths, and measure the precise distribution of telomere lengths in a variety of samples, including mice and human cells. TLA can measure telomere lengths <1 kb and >80 kb, enabling us to have a clearer understanding of the association between telomere length and disease.

In my laboratory, we are investigating how telomere length contributes to cell proliferation and human health, and how telomere maintenance mechanisms become activated in cancer cells. TLA provides a new way to examine telomere length, which can be applied to further understand the underlying mechanisms of telomere dysfunction and telomere length regulation.”

***

ABOUT GENOMIC VISION

Genomic Vision is a biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes.

Genomic Vision proprietary molecular tools provide robust quantitative measurements that are needed to enable high confidence characterization of DNA alteration in the genome. These tools are currently use for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases.

Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document dated March 28, 2017, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions

Contacts

Genomic Vision
Aaron Bensimon

Co-fondateur et Président du Directoire

Tél. : +33 1 49 08 07 50

investisseurs@genomicvision.com

Ulysse Communication
Bruno Arabian

Tel.:+33142682970

barabian@ulysse-communication.com

NewCap
Investor Relations / Strategic Communications

Dušan Orešanský / Emmanuel Huynh

Tél. : +33 1 44 71 94 92

gv@newcap.eu